NICOLE BOYLE: Open Payments
NPI 1275266991 · AMMON, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$846 in 49 payments from 13 companies in 2025. Trend: 2023 $510 · 2024 $577 · 2025 $846
Food & beverage: $846
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $186 |
| Teva Pharmaceuticals USA, Inc. | 11 | $141 |
| Otsuka America Pharmaceutical, Inc. | 9 | $136 |
| Neurocrine BioSciences, Inc. | 7 | $122 |
| JAZZ PHARMACEUTICALS INC. | 2 | $64 |
| ABBVIE INC. | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| Indivior Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $17 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
Products named: CAPLYTA, INGREZZA, AUSTEDO XR, ABILIFY ASIMTUFII, REXULTI, XYWAV, VRAYLAR, FANAPT.
Industry payments across ID — which companies pay providers there.
